Recent Updates
Recently added Catalysts

macitentan

Phase 3

Systemic Sclerosis | Small molecule | Other |Johnson & Johnson|Last Updated: Jan 6, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment289
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01474109Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPHASE3 COMPLETED 289Dec 1, 2011Nov 1, 2013Jan 6, 201577 United States, Australia +16
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence Rate of New Digital Ulcers (DUs) up to Week 16
Baseline to week 16

DUs were assessed at each visit starting with the screening visit. Only DUs from the proximal interphalangeal joint (PIP) distally (both on the dorsal and volar surface of the hand, including the digital tip) were recorded. The location of each DU was noted. At each subsequent visit the location of each new DU was noted. DUs that occurred and healed between visits and were reported by patients were not recorded as new DUs. The evaluation was performed by an experienced physician or a trained rater with expertise in the assessment of DUs in systemic sclerosis (SSc). For a given patient, DUs were assessed by the same rater at each visit, whenever possible. Any DU that developed over a previously healed ulcer was recorded as a new DU. Incidence rate is adjusted for 16 weeks of observation, hence is calculated as the number of new DUs/total number of observation days.

Secondary Endpoints
Percentage of Participants Without a New DU Up To Week 16
Baseline to week 16
Percentage of Participants With at Least One DU Complication
Up to approximately 90 weeks
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16
Baseline to week 16
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
macitentan 3mgACTIVE_COMPARATORmacitentan 3mg tablet once daily
macitentan 10mgACTIVE_COMPARATORmacitentan 10mg tablet once daily
placeboPLACEBO_COMPARATORmatching placebo once daily
Interventions
NameTypeDescription
macitentan 3mgDRUGmacitentan 3mg tablet once daily
macitentan 10mgDRUGmacitentan 10mg tablet once daily
placeboDRUGmatching placebo once daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites77

Inclusion Criteria : * Patients ≥ 18 years of age * Women of childbearing potential must use two reliable methods of contraception * Diagnosis of SSc according to the classification criteria of the American College of Rheumatology (ACR) * At least one visible, active ischemic digital ulcers (DU) at...

Countries:United StatesAustraliaBelarusBulgariaCanadaChileColombiaCroatiaCzechiaDenmarkFinlandGermanyHungaryIndiaItalyPolandRussiaUkraine
Unlock Eligibility Criteria